Generate a tailored SOP for Dr. Graeme Hewitt. Improve your application with a focused, well-structured draft.
Graeme Hewitt is a Junior Group Leader at Cancer Research UK's RadNet within King's College London's Comprehensive Cancer Centre. He received his PhD in 2016 from Newcastle University, where he was awarded the Medical Sciences Doctoral Thesis Prize for his research on the interplay of protein degradation pathways in autophagy and DNA double-strand break repair. Following his PhD, Graeme completed postdoctoral research at the Francis Crick Institute in London under the mentorship of Simon Boulton. He has significant experience in developing cell-based assays for drug discovery while seconded to Artios Pharma in Cambridge, focusing on DNA damage response mechanisms pertinent to cancer treatment. His recent work has led to the identification of ALC1 as a potential therapeutic target in ATM-HRD-deficient cancers. In 2021, Graeme was awarded the CRUK RadNet fellowship to initiate an independent research program leveraging CRISPR screens and proteomics to understand genetic dependencies in cancer cells. He is an expert in DNA damage response and has published various research articles highlighting the functional mechanisms of chromatin remodelers and their implications in cancer biology.
Cancer Research UK RadNet • London, UK
Leads a research program focused on targeting DNA damage response in conjunction with radiotherapy.
Francis Crick Institute • London, UK
Conducted research on DNA damage response mechanisms and chromatin remodeling in cancer.
Requirements are consistent across King's Business School and Social Science & Public Policy departments for standard Master's entries.